__timestamp | Intra-Cellular Therapies, Inc. | Viatris Inc. |
---|---|---|
Wednesday, January 1, 2014 | 21226345 | 581800000 |
Thursday, January 1, 2015 | 87718074 | 671900000 |
Friday, January 1, 2016 | 93831530 | 876700000 |
Sunday, January 1, 2017 | 79419009 | 857900000 |
Monday, January 1, 2018 | 132166913 | 822200000 |
Tuesday, January 1, 2019 | 89124838 | 778200000 |
Wednesday, January 1, 2020 | 65782137 | 512600000 |
Friday, January 1, 2021 | 88845513 | 681000000 |
Saturday, January 1, 2022 | 134715000 | 662200000 |
Sunday, January 1, 2023 | 180142000 | 910700000 |
Data in motion
In the ever-evolving pharmaceutical landscape, research and development (R&D) spending is a critical indicator of innovation and future growth. Over the past decade, Viatris Inc. and Intra-Cellular Therapies, Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Viatris Inc. consistently outspent Intra-Cellular Therapies, with its R&D expenses peaking at approximately 910 million in 2023, a 56% increase from its 2014 spending. In contrast, Intra-Cellular Therapies, Inc. showed a more dynamic growth trajectory, with its R&D spending surging by over 740% during the same period, reaching around 180 million in 2023. This divergence highlights Viatris's steady commitment to innovation, while Intra-Cellular Therapies, Inc. has rapidly scaled its efforts, potentially signaling a strategic pivot towards aggressive growth and development. As these companies continue to invest in R&D, their future breakthroughs could reshape the pharmaceutical industry.
Research and Development Expenses Breakdown: argenx SE vs Intra-Cellular Therapies, Inc.
Research and Development Investment: Genmab A/S vs Intra-Cellular Therapies, Inc.
Comparing Innovation Spending: Incyte Corporation and Viatris Inc.
Research and Development Investment: Viatris Inc. vs Corcept Therapeutics Incorporated
Who Prioritizes Innovation? R&D Spending Compared for Viatris Inc. and ADMA Biologics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Viatris Inc. and ACADIA Pharmaceuticals Inc.
Comparing Innovation Spending: Viatris Inc. and HUTCHMED (China) Limited
Who Prioritizes Innovation? R&D Spending Compared for Viatris Inc. and Supernus Pharmaceuticals, Inc.
Viatris Inc. or Amphastar Pharmaceuticals, Inc.: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for Intra-Cellular Therapies, Inc. and Madrigal Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Intra-Cellular Therapies, Inc. vs Amicus Therapeutics, Inc.
Intra-Cellular Therapies, Inc. or Mesoblast Limited: Who Invests More in Innovation?